# EDGAR Filing Document

**Accession Number:** 0001985062
**File Stem:** 0001213900-25-057779
**Filing Date:** 2025-6
**Character Count:** 98523
**Document Hash:** f271a6e729629068ae5b2c68cb244a7f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-057779.hdr.sgml**: 20250625

**ACCESSION NUMBER**: 0001213900-25-057779

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20250625

**FILED AS OF DATE**: 20250625

**DATE AS OF CHANGE**: 20250625

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PSYENCE BIOMEDICAL LTD.
- **CENTRAL INDEX KEY:** 0001985062
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41937
- **FILM NUMBER:** 251073586

**BUSINESS ADDRESS:**
- **STREET 1:** 121 RICHMOND STREET WEST PENTHOUSE
- **STREET 2:** SUITE 1300
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5H 2K1
- **BUSINESS PHONE:** 27744604171

**MAIL ADDRESS:**
- **STREET 1:** 121 RICHMOND STREET WEST PENTHOUSE
- **STREET 2:** SUITE 1300
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5H 2K1

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THESECURITIES**

**EXCHANGE ACT OF 1934**

For the month of **June 2025**

Commission File Number: **001-41937**

**Psyence Biomedical Ltd.** 

(Translation of registrant's name into English)

**121 Richmond Street West**

**Penthouse Suite 1300**

**Toronto, Ontario M5H 2K1**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☒ Form 20-F ☐ Form 40-F

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1 | [Psyence Biomedical Ltd. 2023 Equity Incentive Plan, as amended](ea024690601ex10-1_psyence.htm) |
| 99.1 | [Press Release, dated June 18, 2025](ea024690601ex99-1_psyence.htm) |
| 99.2 | [Press Release, dated June 17, 2025](ea024690601ex99-2_psyence.htm) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: June 25, 2025

---

| | |
|:---|:---|
| **Psyence Biomedical Ltd.** | **Psyence Biomedical Ltd.** |
| By: | /s/ Dr. Neil Maresky |
| Name: | Dr. Neil Maresky |
| Title: | Chief Executive Officer and Director |

---

## Exhibit 10.1

**Exhibit 10.1**

---

| |
|:---|
| **Execution Version as amended by the board on June 28, 2024, and** |
| **shareholders on November 12, 2024, corrected June 17, 2025** |

---

**PSYENCE BIOMEDICAL LTD.**

**2023 EQUITY INCENTIVE PLAN**

1. <u>Purpose</u>. The purposes of this Plan are to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) attract, retain, and motivate Employees, Directors, and Consultants,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) provide additional incentives to Employees, Directors, and Consultants, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) promote the success of the Company's business,

by providing Employees, Directors, and Consultants with opportunities to acquire the Company's Shares, or to receive monetary payments based on the value of such Shares. Additionally, the Plan is intended to assist in further aligning the interests of the Company's Employees, Directors, and Consultants to those of its shareholders.

2. <u>Definitions</u>. As used herein, the following definitions will apply:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) " <u>Administrator</u> " means a committee of at least one Director of the Company as the Board may appoint to administer
this Plan or, if no such committee has been appointed by the Board, the Board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) " <u>Applicable Laws</u> " means the requirements relating to the administration of equity-based awards or equity compensation
plans under corporate laws, securities laws, the Code, any stock exchange or quotation system on which the Shares are listed or quoted
and the applicable laws of any foreign country or jurisdiction where Awards are, or will be, granted under the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) " <u>Award</u> " means, individually or collectively, a grant under the Plan of Share Options, Share Appreciation Rights,
Restricted Shares, Restricted Share Units, or Other Share-Based Awards.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) " <u>Award Agreement</u> " means the written or electronic agreement, consistent with the terms of the Plan, between the
Company and the Participant, setting forth the terms, conditions, and restrictions applicable to each Award granted under the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) " <u>Board</u> " means the Company's Board of Directors, as constituted from time to time and, where the context so
requires, reference to the "Board" may refer to a committee to whom the Board has delegated
authority to administer any aspect of this Plan.

**Execution Version**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) " <u>Cause</u> " shall have the meaning ascribed to such term, or term of similar effect, in any offer letter, employment,
consulting, severance, or similar agreement, including any Award Agreement, between the Participant and the Company or any Subsidiary;
provided, that in the absence of an offer letter, employment, severance, or similar agreement containing such definition, "Cause"
means:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) any willful, material violation by the Participant of any law or regulation applicable to the business of the Company, a Subsidiary,
or other affiliate of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the Participant's conviction for, or guilty plea to, a felony (or crime of similar magnitude under Applicable Laws) or a crime
involving moral turpitude, or any willful perpetration by the Participant of a common law fraud, act of material dishonesty, embezzlement,
or misappropriation or similar conduct against the Company, a Subsidiary, or other affiliate of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) the Participant's commission of an act of personal dishonesty which involves personal profit in connection with the Company,
a Subsidiary, other affiliate of the Company, or any other entity having a business relationship with any of the foregoing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) any material breach or violation by the Participant of any fiduciary duties or duties of care to the Company or provision of any agreement
or understanding between the Company, a Subsidiary, or other affiliate of the Company and the Participant regarding
the terms of the Participant's service as an Employee, officer, Director, or Consultant to the Company, a Subsidiary, or other affiliate
of the Company, including without limitation, the willful and continued failure or refusal of the Participant to perform the material
duties required of such Participant as an Employee, officer, Director, or Consultant of the Company, a Subsidiary, or other affiliate
of the Company, other than as a result of having a Disability, or a breach of any applicable invention assignment, confidentiality, non-
competition, non-solicitation, restrictive covenant, or similar agreement between the Company, a Subsidiary, or other affiliate of the
Company and the Participant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) the Participant's gross misconduct or incompetence in the performance of the Participant's duties or obligations to the
Company, a Subsidiary, or other affiliate of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) any refusal by the Participant to carry out a reasonable directive of the chief executive officer, the Board or the Participant's
direct supervisor, which involves the business of the Company, a Subsidiary, or other affiliate of the Company and was capable of being
lawfully performed;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) the Participant's violation of the code of ethics of the Company or any Subsidiary;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) the Participant's disregard of the policies of the Company, a Subsidiary, or other affiliate of the Company so as to cause loss,
harm, damage, or injury to the property, reputation, or employees of the Company, a Subsidiary, or other affiliate of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) any other misconduct by the Participant that is injurious to the financial condition or business reputation of, or is otherwise injurious
to, the Company, a Subsidiary, or other affiliate of the Company; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) any other act, omission, or circumstance that constitutes cause at law to terminate the employment of an employee without notice or
compensation in lieu of notice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) " <u>Change in Control</u> " means the occurrence
of any of the following events:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the "beneficial owner"
(as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%)
or more of the total voting power represented by the Company's then
outstanding voting securities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) a change in the composition of the Board occurring within a two-year period, as a result of which
 fewer than a majority of the directors are Incumbent Directors. "Incumbent Directors" means directors who either (A) are
 Directors as of the Effective Date, or (B) are elected, or nominated for election, to the Board with the affirmative votes of at
 least a majority of the Incumbent Directors at the time of such election or nomination (but will not include an individual whose
 election or nomination is in connection with an actual or threatened proxy contest relating to the election of directors to the
 Company); or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) the consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which
would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining
outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total
voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after
such merger or consolidation.

Notwithstanding the foregoing, a transaction shall not constitute a Change in Control if its sole purpose is to change the jurisdiction of the Company's incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company's securities immediately before such transaction. In addition, if a Change in Control constitutes a payment event with respect to any Award which provides for a deferral of compensation and is subject to Code Section 409A, then notwithstanding anything to the contrary in the Plan or applicable Award Agreement, the transaction with respect to such Award must also constitute a "change in control event" as defined in Treasury Regulation Section 1.409A- 3(i)(5) to the extent required by Code Section 409A.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) " <u>Code</u> " means the U.S. Internal Revenue Code of 1986, as amended. Any reference to a section of the Code herein
will be a reference to any successor or amended section of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) " <u>Company</u> " means Psyence Biomedical Ltd., a corporation organized under the laws of Ontario, Canada, or any successor
thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) " <u>Consultant</u> " means a consultant or adviser who provides *bona fide* services to the Company, its Parent, or
any Subsidiary as an independent contractor and who qualifies as a consultant or advisor under Instruction A.1.(a)(1) of Form S-8 under
the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) " <u>Director</u> " means a member of the Board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) " <u>Disability</u> " means total and permanent disability as defined in Code Section 22(e)(3), provided that in the case
of an Award other than an Incentive Share Option, the Administrator in its discretion may determine whether a permanent and total disability
exists in accordance with uniform and non-discriminatory standards adopted by the Administrator from time to time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) " <u>Effective Date</u> " shall have the meaning set forth in Section 24.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) " <u>Employee</u> " means any person, including officers and Directors, employed by the Company, its Parent, or any Subsidiary.
Neither service as a Director nor payment of a director's fee by the
Company will be sufficient to constitute "employment" by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) " <u>Exchange Act</u> " means the U.S. Securities Exchange Act of 1934, as amended.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) " <u>Fair Market Value</u> " means, as of any date, the value of a Share, determined as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) if the Shares are readily tradable on an established securities market, its Fair Market Value will be the volume weighted average
trading price for such shares during the thirty (30) days immediately preceding the day of determination;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) if the Shares are regularly quoted by a recognized securities dealer but selling prices are not reported, its Fair Market Value will
be the mean between the high bid and low asked prices for a Share for the day of determination, as reported in <u>The Wall Street Journal</u> or such other source as the Administrator deems reliable; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) if the Shares are not readily tradable on an established securities market, the Fair Market Value will be determined in good faith
by the Administrator.

Notwithstanding the preceding, for federal, state, and local income tax reporting purposes and for such other purposes as the Administrator deems appropriate, Fair Market Value shall be determined by the Administrator in accordance with uniform and nondiscriminatory standards adopted by it from time to time. In addition, the determination of Fair Market Value in all cases shall be in accordance with the requirements set forth under Code Section 409A to the extent necessary for an Award to comply with, or be exempt from, Code Section 409A. The Administrator's determination shall be conclusive and binding on all persons.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q) " <u>Incentive Share Option</u> " means a Share Option intended to qualify as an incentive stock option within the meaning
of Code Section 422 and the regulations promulgated thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r) " <u>Non-Employee Director</u> " means a Director who is a "non-employee director" within the meaning of Exchange
Act Rule 16b-3.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s) " <u>Nonqualified Share Option</u> " means a Share Option that by its terms, or in operation, does not qualify or is not
intended to qualify as an Incentive Share Option.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t) " <u>Other Share-Based Awards</u> " means any other awards not specifically described in the Plan that are valued in whole

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(u) " <u>Parent</u> " means a "parent corporation," whether now or hereafter existing, as defined in Code Section
424(e).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) " <u>Participant</u> " means the holder of an outstanding Award granted under the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(w) " <u>Period of Restriction</u> " means the period during which the transfer of Restricted Shares is subject to restrictions
and a substantial risk of forfeiture. Such restrictions may be based on the passage of time, the achievement of certain performance criteria,
or the occurrence of other events as determined by the Administrator.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) " <u>Plan</u> " means this Psyence Biomedical Ltd. 2023 Equity Incentive Plan, as amended and restated.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(y) " <u>Restricted Shares</u> " means Shares, subject to a Period of Restriction or certain other specified restrictions (including,
without limitation, a requirement that the Participant remain continuously employed or provide continuous services for a specified period
of time), granted under Section 9 or issued pursuant to the early exercise of a Share Option.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(z) " <u>Restricted Share Unit</u> " or " <u>RSU</u> " means an unfunded and unsecured promise to deliver Shares,
cash, other securities, or other property, subject to certain restrictions (including, without limitation, a requirement that the Participant
remain continuously employed or provide continuous services for a specified period of time), granted under Section 10.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(aa) " <u>Service</u> " means service as a Service Provider. In the event of any dispute over whether and when Service has terminated,
the Administrator shall have sole discretion to determine whether such termination has occurred and the effective date of such termination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(bb) " <u>Service Provider</u> " means an Employee, Director, or Consultant, including any prospective Employee, Director, or
Consultant who has accepted an offer of employment or service and will be an Employee, Director, or Consultant after the commencement
of their service.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(cc) " <u>Share Appreciation Right</u> " or " <u>SAR</u> " means an Award pursuant to Section 8 that is designated
as a SAR.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(dd) " <u>Shares</u> " means the Company's common
shares without par value.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ee) " <u>Share Option</u> " means an option granted pursuant to the Plan to purchase Shares, whether designated as an Incentive
Share Option or a Nonqualified Share Option.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ff) " <u>Subsidiary</u> " means a "subsidiary corporation," whether now or hereafter existing, as defined in Code
Section 424(f).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(gg) " <u>Substitute Award</u> " has the meaning set
forth in Section 3(d).

3. Awards.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Award Types. The Plan permits the
grant of Share Options, Share Appreciation Rights, Restricted Share, Restricted Share Units, and Other Share-Based Awards.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Award Agreements</u>. Awards shall be evidenced by Award Agreements (which need not be identical) in such forms as the Administrator
may from time to time approve; <u>provided</u>, <u>however</u>, that in the event of any conflict between the provisions of the Plan and
any such Award Agreements, the provisions of the Plan shall prevail.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Date of Grant</u>. The date of grant of an Award will be, for all purposes, the date on which the Administrator makes the determination
granting such Award, or such later date as is determined by the Administrator, consistent with Applicable Laws. Notice of the determination
will be provided to each Participant within a reasonable time after the date of such grant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Substitute Awards</u>. In connection with an entity's merger or consolidation with the Company, any Subsidiary, or the Company's
or any Subsidiary's acquisition of an entity's property or stock,
the Administrator may grant Awards in substitution for any options or other shares or share-based awards granted before such merger or
consolidation by such entity or its affiliate. Substitute Awards may be granted on such terms as the Administrator deems appropriate,
notwithstanding limitations on Awards in the Plan. Substitute Awards will not count against the Plan Share Limit (nor shall Shares subject
to a Substitute Award be added to the Shares available for Awards under the Plan as provided below in Section 4(c), (d), or (e) below),
except that Shares acquired by exercise of substitute Incentive Share Options will count against the maximum number of Shares that may
be issued pursuant to the exercise of Incentive Share Options under Section 4(f). Additionally, in the event that a company acquired by
the Company or any Subsidiary or with which the Company or any Subsidiary combines has shares available under a pre-existing plan (so
long as not adopted in contemplation of such acquisition or combination), the shares available for grant pursuant to the terms of such
pre-existing plan (as adjusted, to the extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula
used in such acquisition or combination to determine the consideration payable to the holders of common stock of the entities party to
such acquisition or combination) may be used for Awards under the Plan, and shall not reduce the Plan Share Limit (and Shares available
for Awards under the Plan as provided below in Section 4(c), (d), or (e) below); provided that Awards using such available shares shall
not be made after the date awards or grants could have been made under the terms of the pre-existing plan, absent the acquisition or combination,
and shall only be made to individuals who were not Service Providers prior to such acquisition or combination.

4. <u>Shares Available for Awards</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Basic Limitation</u>. Subject to the
 provisions of Section 14, the maximum aggregate number of Shares that may be issued under
 the Plan is **8,150,126** <sup>1</sup> (pre-share consolidation figure) / 13,635 (post-share
 consolidation figure) (the " <u>Plan Share Limit</u> "). The Shares subject to
 the Plan may be authorized, but unissued, or reacquired shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Annual Increase in Available Shares</u>. On the first day of each calendar year during the term of the Plan, commencing on January
1, 2025 and continuing until (and including) January 1, 2034, the number of Shares available under the Plan Share Limit shall automatically
increase by a number equal to the lesser of (i) fifteen percent (15%) of the total number of Shares issued and outstanding on December
31 of the calendar year immediately preceding the date of such increase and (ii) a number of Shares determined by the Board.

<sup>1</sup> Note: On November 12, 2024, shareholders approved the increase of the number of Common Shares reserved for issuance under the Plan by 6,141,527 shares (such number did not take into account the effect of approval of the 75-to-1 share consolidation, nor the 7.97-to-1 share consolidation) to 8,150,126 Common Shares from the 2,008,599 Common Shares initially authorized under the Plan, which amounted to 15% of the fully-diluted outstanding stock immediately following the Closing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Awards Not Settled in Shares Delivered to Participant</u>. Upon payment in Shares pursuant to the exercise or settlement of an
Award, the number of Shares available for issuance under the Plan shall be reduced only by the number of Shares actually issued in such
payment. If a Participant pays the exercise price (or purchase price, if applicable) of an Award through the tender of Shares, or if the
Shares are tendered or withheld to satisfy any tax withholding obligations, the number of the Shares so tendered or withheld shall again
be available for issuance pursuant to future Awards under the Plan, although such Shares shall not again become available for issuance
as Incentive Share Options.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Cash-Settled Awards</u>. Shares shall not be deemed to have been issued pursuant to the Plan with respect to any portion of an
Award that is settled in cash.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Lapsed Awards</u>. If any outstanding Award expires or is terminated or canceled without having been exercised or settled in full,
or if the Shares acquired pursuant to an Award subject to forfeiture or repurchase are forfeited or repurchased by the Company, the Shares
allocable to the terminated portion of such Award or such forfeited or repurchased Shares shall again be available for grant under the
Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Code Section 422 Limitations</u>. No more than **8,150,126** <sup>2</sup> Shares (subject to adjustment pursuant to Section 14)
may be issued under the Plan upon the exercise of Incentive Share Options.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Share Reserve</u>. The Company, during the term of the Plan, shall at all times keep available such number of Shares authorized
for issuance as will be sufficient to satisfy the requirements of the Plan.

5. <u>Administration</u>. The Plan will be administered by the Administrator.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Powers of the Administrator</u>. Subject to the provisions of the Plan, the Administrator will have the authority, in its discretion
to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) determine Fair Market Value;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) select the Service Providers to whom Awards may be granted;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) determine the type or types of Awards to be granted to Participants under the Plan and number of the Shares to be covered by each
Award;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) approve forms of Award Agreements for use under the Plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) determine the terms and conditions, not inconsistent with the terms of the Plan, of any Award. Such terms and conditions include,
but are not limited to, the exercise price, the time or times when Awards may be exercised (which may be based on performance criteria),
any vesting criteria or Periods of Restriction, any vesting acceleration or waiver of forfeiture or repurchase restrictions, and any restriction
or limitation regarding any Award or the Shares relating thereto, based in each case on such factors as the Administrator, in its sole
discretion, will determine;

 

<sup>2</sup> Note: This will be the same number as the Plan Share Limit in Section 4(a).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) construe and interpret the terms of the Plan, any Award Agreement, and Awards granted pursuant to the Plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) prescribe, amend, and rescind rules and regulations relating to the Plan, including rules and regulations relating to sub-plans established
for the purpose of satisfying applicable foreign laws and/or qualifying for preferred tax treatment under applicable tax laws;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) modify or amend each Award (subject to Section 18(c)), including (A) the discretionary authority to extend the post-termination exercisability
period of Awards and (B) accelerate the satisfaction of any vesting criteria or waiver of forfeiture or repurchase restrictions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) allow Participants to satisfy withholding tax obligations by electing to have the Company withhold from the Shares or cash to be issued
upon exercise or vesting of an Award that number of the Shares or cash having a Fair Market Value equal to the amount required to be withheld.
The Fair Market Value of any Shares to be withheld will be determined on the date that the amount of tax to be withheld is to be determined.
All elections by a Participant to have Shares or cash withheld for this purpose will be made in such form and under such conditions as
the Administrator may deem necessary or advisable;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) authorize any person to execute on behalf of the Company any instrument required to effect the grant of an Award previously granted
by the Administrator;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi) allow a Participant to defer the receipt of the payment of cash or the delivery of the Shares that would otherwise be due to such
Participant under an Award, subject to compliance (or exemption) from Code Section 409A;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii) determine whether Awards will be settled in cash, Shares, other securities, other property, or in any combination thereof;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiii) determine whether Awards will be adjusted for dividend equivalents;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiv) create Other Stock-Share Awards for issuance under the Plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xv) impose such restrictions, conditions, or limitations as it determines appropriate as to the timing and manner of any resales by a
Participant or other subsequent transfers by the Participant of any securities issued as a result of or under an Award, including without
limitation, (A) restrictions under an insider trading policy, and (B) restrictions as to the use of a specified brokerage firm for such
resales or other transfers; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xvi) make all other determinations and take any other action deemed necessary or advisable for administering the Plan and due
 compliance with Applicable Laws, stock market or
exchange rules or regulations or accounting or tax rules or regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Prohibition on Repricing</u>. Notwithstanding anything to the contrary in Section 5(a) and except for
an adjustment pursuant to Section 14 or a repricing approved by shareholders, in no case may the Administrator (i) amend an outstanding
Share Option or SAR Award to reduce the exercise price of the Award, (ii) cancel, exchange, or surrender an outstanding Share Option or
SAR in exchange for cash or other awards for the purpose of repricing the Award, or (iii) cancel, exchange, or surrender an outstanding
Share Option or SAR in exchange for a Share Option or SAR with an exercise price that is less than the exercise price of the original
Award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Section 16</u>. To the extent desirable to qualify transactions hereunder as exempt under Exchange
Act Rule 16b-3, the transactions contemplated hereunder will be approved by the entire Board or a committee of two or more Non-Employee
Directors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Delegation of Authority</u>. Except to the extent prohibited by Applicable Laws, the Administrator
may delegate to one or more officers of the Company some or all of its authority under the Plan, including the authority to grant all
types of Awards, in accordance with Applicable Law (except that such delegation shall not apply to any Award for a Participant then covered
by Section 16 of the Exchange Act), and the Administrator may delegate to one or more committees of the Board (which may consist solely
of one Director) some or all of its authority under this Plan, including the authority to grant all types of Awards, in accordance with
Applicable Law. Such delegation may be revoked at any time. The acts of such delegates shall be treated as acts of the Administrator,
and such delegates shall report regularly to the Administrator regarding the delegated duties and responsibilities and any Awards granted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Effect of Administrator's Decision</u>. The Administrator's decisions, determinations, and interpretations will be
final and binding on all persons, including Participants and any other holders of Awards.

6. <u>Eligibility</u>. The Administrator has the discretion to select any Service Provider to receive an Award, although Incentive Share
Options may be granted only to Employees. Designation of a Participant in any year shall not require the Administrator to designate such
person to receive an Award in any other year or, once designated, to receive the same type or amount of Award as granted to the Participant
in any other year. The Administrator shall consider such factors as it deems pertinent in selecting Participants and in determining the
type and amount of their respective Awards.

7. <u>Share Options</u>. The Administrator, at any time and from time to time, may grant Share Options under the Plan to Service Providers.
Each Share Option shall be subject to such terms and conditions consistent with the Plan as the Administrator may impose from time to
time, subject to the following limitations:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Exercise Price</u>. The per share exercise price for Shares to be issued pursuant to exercise of a Share Option will be determined
by the Administrator, but shall be no less than 100% of the Fair Market Value per Share on the date of grant, subject to Section 7(e).
Notwithstanding the foregoing, in the case of a Share Option that is a Substitute Award, the exercise price for Shares subject to such
Share Option may be less than the Fair Market Value per Share on the date of grant; provided that the exercise price of any Substitute
Award shall be determined in accordance with the applicable requirements of Code Sections 424 and 409A.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Exercise Period</u>. Share Options granted under the Plan shall be exercisable at such time or times and subject to such terms
and conditions as shall be determined by the Administrator; <u>provided</u>, <u>however</u>, that no Share Option shall be exercisable
later than ten (10) years after the date it is granted. Share Options shall terminate at such earlier times and upon such conditions or
circumstances as the Administrator shall in its discretion set forth in such Award Agreement at the date of grant; <u>provided</u>, <u>however</u>,
the Administrator may, in its sole discretion, later waive any such condition.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Payment of Exercise Price</u>. To the extent permitted by Applicable Laws, the Participant may pay the Share Option exercise price
by:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) cash;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) check;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) surrender of other Shares which meet the conditions established by the Administrator to avoid adverse accounting consequences to the
Company (as determined by the Administrator);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) if approved by the Administrator, as determined in its sole discretion, by a broker-assisted cashless exercise in accordance with
procedures approved by the Administrator, whereby payment of the exercise price may be satisfied, in whole or in part, with Shares subject
to the Share Option by delivery of an irrevocable direction to a securities broker (on a form prescribed by the Administrator) to sell
Shares and to deliver all or part of the sale proceeds to the Company in payment of the aggregate exercise price;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) if approved by the Administrator for a Nonqualified Share Option, as determined in its sole discretion, by delivery of a notice of
"net exercise" to the Company, pursuant to which the Participant shall receive the number of Shares underlying the Share Option
so exercised reduced by the number of Shares equal to the aggregate exercise price of the Share Option divided by the Fair Market Value
on the date of exercise;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) such other consideration and method of payment for the issuance of Shares to the extent permitted by Applicable Laws; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) any combination of the foregoing methods of payment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Exercise of Share Option</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Procedure for Exercise</u>. Any Share Option granted hereunder will be exercisable according to the terms of the Plan and at such
times and under such conditions as determined by the Administrator and set forth in the Award Agreement. A Share Option may not be exercised
for a fraction of a Share. Exercising a Share Option in any manner will decrease the number of Shares thereafter available for purchase
under the Share Option, by the number of Shares as to which the Share Option is exercised.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Exercise Requirements</u>. A Share Option will be deemed exercised when the Company receives: (A) written or electronic notice
of exercise (in accordance with the Award Agreement) from the person entitled to exercise the Share Option, and (B) full payment of the
exercise price (including provision for any applicable tax withholding).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) <u>Non-Exempt Employees</u>. If a Share Option is granted to an Employee who is a non-exempt employee for purposes of the U.S. Fair
Labor Standards Act of 1938, as amended, the Share Option will not be first exercisable for any Shares until at least six (6) months following
the date of grant of the Share Option (although the Share Option may vest prior to such date). Consistent with the provisions of the Worker
Economic Opportunity Act, (A) if such non-exempt Employee dies or suffers a Disability, (B) upon a Change in Control in which such Share
Option is not assumed, continued, or
substituted, or (C) upon the Participant's retirement (as such term may be defined in the Participant's Award Agreement,
in another agreement between the Participant and the Company or a Subsidiary, or, if no such definition, in accordance with the then
current employment policies and guidelines of the Company or employing Subsidiary), the vested portion of any Share Option may be
exercised earlier than six (6) months following the date of grant. The foregoing provision is intended to operate so that any income
derived by a non-exempt employee in connection with the exercise or vesting of a Share Option will be exempt from the
Participant's regular rate of pay. To the extent permitted and/or required for compliance with the U.S. Worker Economic
Opportunity Act to ensure that any income derived by a non-exempt employee in connection with the exercise, vesting, or issuance of
any Shares under any other Award will be exempt from the employee's regular rate of pay, the provisions of this Section
7(d)(iii) will apply to all Awards and are hereby incorporated by reference into such Award Agreements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) <u>Termination of Relationship as a Service Provider</u>. If a Participant ceases to be a Service Provider, the Participant may exercise
the Share Option within such period of time as is specified
in the Award Agreement to the extent that the Share Option is vested on the date of termination (but in no event later than the expiration
of the term of such Share Option as set forth in the Award Agreement). In the absence of a specified time in the Award Agreement, the
Share Option will remain exercisable for three (3) months (or twelve (12) months in the case of termination on account of Disability or
death) following the Participant's termination. If a Participant commits an act of Cause, all vested and unvested Share Options
shall be forfeited as of such date. Unless otherwise provided by the Administrator, if on the date of termination the Participant is not
vested as to a Share Option, the Shares covered by the unvested portion of the Share Option will be forfeited and will revert to the Plan
and again will become available for grant under the Plan. If after termination, the Participant does not exercise a Share Option as to
all of the vested Shares within the time specified by the Administrator, the Share Option will terminate, and remaining Shares covered
by such Share Option will be forfeited and will revert to the Plan and again will become available for grant under the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) <u>Extension of Exercisability</u>. A Participant may not exercise a Share Option at any time that the issuance of Shares upon such
exercise would violate Applicable Laws. Except as otherwise provided in the Award Agreement, if a Participant ceases to be a Service Provider
for any reason other than for Cause and, at any time during the last thirty (30) days of the applicable post-termination exercise period:
(A) the exercise of the Participant's Share Option would be prohibited solely because the issuance of Shares upon such exercise
would violate Applicable Laws, or (B) the immediate sale of any Shares
issued upon such exercise would violate the Company's trading policy, then the applicable post- termination exercise period will
be extended to the last day of the calendar month that commences following the date the Award would otherwise expire, with an additional
extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any
time during such extended exercise period, generally without limitation as to the maximum permitted number of extensions); <u>provided</u>, <u>however</u>, that in no event may such Award be exercised after the expiration of its maximum term.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) <u>Beneficiary</u>. If a Participant dies while a Service Provider, the Share Option may be exercised following the Participant's
death by the Participant's designated beneficiary,
provided such beneficiary has been designated and received by the Administrator prior to the Participant's death in a form acceptable
to the Administrator. If no such beneficiary has been properly designated by the Participant, then such Share Option may be exercised
by the personal representative of the Participant's estate or by the persons to whom the Share Option is transferred pursuant to
the Participant's will or in accordance with the laws of descent and distribution.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) <u>Shareholder Rights</u>. Until the Shares are issued (as evidenced by the appropriate entry on the books of the Company or of a
duly authorized transfer agent or depositary of the Company), no right to vote or receive dividends or any other rights as a shareholder
will exist with respect to the Shares, notwithstanding the exercise of the Share Option. No adjustment will be made for a dividend or
other right for which the record date is prior to the date the Shares are issued, except as provided in Section 14 or the applicable Award
Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Incentive Share Option Limitations</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Each Share Option will be designated in the Award Agreement as either an Incentive Share Option or a Nonqualified Share Option. However,
notwithstanding such designation, to the extent that the aggregate Fair Market Value of the Shares with respect to which Incentive Share
Options are exercisable for the first time by the Participant during any calendar year (under all plans of the Company, its Parent, or
any Subsidiary) exceeds US$100,000, such Share Options will be treated as Nonqualified Share Options. For purposes of this Section 7(e)(i),
Incentive Share Options will be taken into account in the order in which they were granted. The Fair Market Value of the Shares will be
determined as of the time the Share Option is granted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) In the case of an Incentive Share Option, the term will be ten (10) years from the date of grant or such shorter term as may be provided
in the Award Agreement. Moreover, in the case of an Incentive Share Option granted to a Participant who, at the time the Incentive Share
Option is granted, owns shares representing more than ten percent (10%) of the total combined voting power of all classes of stock of
the Company, its Parent, or any Subsidiary, the term of the Incentive Share Option will be five (5) years from the date of grant or such
shorter term as may be provided in the Award Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) No Share Option shall be treated as an Incentive Share Option unless this Plan has been approved by the shareholders of the Company
in a manner intended to comply with the shareholder approval requirements of Code Section 422(b)(1), provided that any Share Option intended
to be an Incentive Share Option shall not fail to be effective solely on account of a failure to obtain such approval, but rather such
Share Option shall be treated as a Nonqualified Share Option unless and until such approval is obtained.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) In the case of an Incentive Share Option, the terms and conditions of such grant shall be subject to and comply with such rules as
may be prescribed by Code Section 422. If for any reason
a Share Option intended to be an Incentive Share Option (or any portion thereof) shall not qualify as an Incentive Share Option, then,
to the extent of such nonqualification, such Share Option or portion thereof shall be regarded as a Nonqualified Share Option appropriately
granted under this Plan.

8. <u>Share Appreciation Rights</u>. The Administrator, at any time and from time to time, may grant SARs to Service Providers. Each
SAR shall be subject to such terms and conditions, consistent with the Plan, as the Administrator may impose from time to time, subject
to the following limitations:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>SAR Award Agreement</u>. Each SAR Award will be evidenced by an Award Agreement that will specify the exercise price, the term
of the SAR, the conditions of exercise, and such other terms and conditions as the Administrator, in its sole discretion, will determine.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Number of Shares</u>. The Administrator will have complete discretion to determine the number of Shares subject to any SAR Award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Exercise Price and Other Terms</u>. The per share exercise price for the Shares that will determine the amount of the payment to
be received upon exercise of a SAR will be determined by the Administrator and will be no less than one hundred percent (100%) of the
Fair Market Value per Share on the date of grant. Notwithstanding the foregoing, in the case of a SAR that is a Substitute Award, the
exercise price for Shares subject to such SAR may be less than the Fair Market Value per Share on the date of grant; provided that the
exercise price of any Substitute Award shall be determined in accordance with the applicable requirements of Code Sections 424 and 409A.
Otherwise, the Administrator, subject to the provisions of the Plan, will have complete discretion to determine the terms and conditions
of SARs granted under the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Expiration of Share Appreciation Rights</u>. A SAR granted under the Plan will expire upon the date determined by the Administrator,
in its sole discretion, and set forth in the Award Agreement. Notwithstanding the foregoing, the rules of Section 7(d) relating to the
maximum term and exercise also will apply to SARs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Payment of Share Appreciation Right Amount</u>. Upon exercise of a SAR, a Participant will be entitled to receive payment from
the Company in an amount determined by multiplying:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The difference between the Fair Market Value of a Share on the date of exercise over the exercise price; times

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The number of Shares with respect to which the SAR is exercised.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Payment Form</u>. At the discretion of the Administrator, the payment upon SAR exercise may be in cash, in Shares, other securities,
or other property of equivalent value, or in some combination thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Tandem Awards</u>. Any Share Option granted under this Plan may include tandem SARs (<u>i.e.</u>, SARs granted in conjunction with
an Award of Share Options under this Plan). The Administrator also may award SARs to a Service Provider independent of any Share Option.

9. <u>Restricted Shares</u>. The Administrator, at any time and from time to time, may grant Restricted Shares to Service Providers in
such amounts as the Administrator, in its sole discretion, will determine, subject to the following limitations:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Restricted Share Agreement</u>. Each Award of Restricted Shares will be evidenced by an Award Agreement that will specify the Period
of Restriction and the applicable restrictions, the number of Shares granted, and such other terms and conditions as the Administrator,
in its sole discretion, will determine. Restricted Shares may be awarded in consideration for (i) cash, check, bank draft or money order
payable to the Company, (ii) past services to the Company, its Parent, or any Subsidiary, or (iii) any other form of legal consideration
that may be acceptable to the Administrator, in its sole discretion, and permissible under Applicable Laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Removal of Restrictions</u>. Unless the Administrator determines otherwise, Restricted Shares will be held by the Company as escrow
agent until the restrictions on such Award have lapsed. The Administrator, in its discretion, may accelerate the time at which any restrictions
will lapse or be removed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Voting Rights</u>. During the Period of Restriction, a Participant holding Restricted Shares may exercise the voting rights applicable
to those Shares, unless the Administrator determines otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Dividends and Other Distributions</u>. During the Period of Restriction, a Participant holding Restricted Shares will be entitled
to receive all dividends and other distributions paid with respect to such Restricted Shares unless otherwise provided in the Award Agreement.
If any such dividends or distributions are paid in Shares, such Shares will be subject to the same restrictions on transferability and
forfeitability as the Restricted Shares with respect to which they were paid.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Transferability</u>. Restricted Shares may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated
until the end of the applicable Period of Restriction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Return of Restricted Shares to Company</u>. On the date set forth in the Award Agreement, the Restricted Shares for which restrictions
have not lapsed will be forfeited and will revert to the Company and again will become available for grant under the Plan.

10. <u>Restricted Share Units (RSUs)</u>. The Administrator, at any time and from time to time, may grant RSUs under the Plan to Service
Providers. Each RSU shall be subject to such terms and conditions, consistent with the Plan, as the Administrator may impose from time
to time, subject to the following limitations:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>RSU Award Agreement</u>. Each Award of RSUs will be evidenced by an Award Agreement that will specify
the terms, conditions, and restrictions related to the grant, including the number of RSUs and such other terms and conditions as the
Administrator, in its sole discretion, will determine.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Vesting Criteria and Other Terms</u>. The Administrator will set vesting criteria in its discretion, which, depending on the extent
to which the criteria are met, will determine the number of RSUs that will be paid out to the Participant. The Administrator may set vesting
criteria based upon the achievement of Company- wide, business unit, or individual goals (including, but not limited to, continued employment
or Service), or any other basis determined by the Administrator in its discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Earning Restricted Share Units</u>. Upon meeting the applicable vesting criteria, the Participant will be entitled to receive a
payout as determined by the Administrator. Notwithstanding the foregoing, at any time after the grant of RSUs, the Administrator, in its
sole discretion, may reduce or waive any vesting criteria that must be met to receive a payout.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Form and Timing of Payment</u>. Payment of earned RSUs will be made as soon as practicable after the date(s) determined by the
Administrator and set forth in the Award Agreement. The Administrator, in its sole discretion, may settle earned RSUs in cash, Shares,
other securities, other property, or a combination of both.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Voting and Dividend Equivalent Rights</u>. The holders of RSUs shall have no voting rights as the Company's shareholders.
Prior to settlement or forfeiture, RSUs awarded under the Plan may, at the
Administrator's discretion, provide for a right to dividend equivalents. Such right entitles the holder to be credited with an amount
equal to all dividends paid on one Share while the RSU is outstanding. Dividend equivalents may be converted into additional RSUs. Settlement
of dividend equivalents may be made in the form of cash, Shares, other securities, other property, or in a combination of the foregoing.
Prior to distribution, any dividend equivalents shall be subject to the same conditions and restrictions as the RSUs to which they attach.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Cancellation</u>. On the date set forth in the Award Agreement, all unearned RSUs will be forfeited to the Company.

11. <u>Other Share-Based Awards</u>. Other Share-Based Awards may be granted either alone, in addition to, or in tandem with, other Awards
granted under the Plan and/or cash awards made outside of the Plan. The Administrator shall have authority to determine the Service Providers
to whom and the time or times at which Other Share-Based Awards shall be made, the amount of such Other Share-Based Awards, and all other
conditions of the Other Share-Based Awards including any dividend and/or voting rights.

12. Vesting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Vesting
Conditions. Each Award may or may not be subject to vesting, a Period of Restriction, and/or other conditions as the Administrator may
determine. Vesting shall occur, in full or in installments, upon satisfaction of the conditions specified in the Award Agreement. Vesting
conditions may include Service- based conditions, performance-based conditions, such other conditions as the Administrator may determine,
or any combination thereof. An Award Agreement may provide for accelerated vesting upon certain specified events.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Performance Criteria</u>. The Administrator may establish performance-based conditions for an Award which may be based on the attainment
of specific levels of performance of the Company (and/or one or more Subsidiaries, divisions, business segments or operational units,
or any combination of the foregoing) and may include, without limitation, any of the following: (i) net earnings or net income (before
or after taxes); (ii) basic or diluted earnings per share (before or after taxes); (iii) revenue or revenue growth (measured on a net
or gross basis); (iv) gross profit or gross profit
growth; (v) operating profit (before or after taxes); (vi) return measures (including, but not limited to, return on assets,
capital, invested capital, equity, or sales); (vii) cash flow (including, but not limited to, operating cash flow, free cash flow,
net cash provided by operations and cash flow return on capital); (viii) financing and other capital raising transactions
(including, but not limited to, sales of the Company's equity or debt securities); (ix) earnings before or after taxes,
interest, depreciation and/or amortization; (x) gross or operating margins; (xi) productivity ratios; (xii) share price (including,
but not limited to, growth measures and total shareholder return); (xiii) expense targets; (xiv) margins; (xv) productivity and
operating efficiencies; (xvi) customer satisfaction; (xvii) customer growth; (xviii) working capital targets; (xix) measures of
economic value added; (xx) inventory control; (xxi) enterprise value; (xxii) sales; (xxiii) debt levels and net debt; (xxiv)
combined ratio; (xxv) timely launch of new facilities; (xxvi) client retention; (xxvii) employee retention; (xxviii) timely
completion of new product rollouts; (xxix) cost targets; (xxx) reductions and savings; (xxxi) productivity and efficiencies; (xxxii)
strategic partnerships or transactions; and (xxxiii) personal targets, goals or completion of projects. Any one or more of the
performance criteria may be used on an absolute or relative basis to measure the performance of the Company and/or one or more
Subsidiaries as a whole or any business unit(s) of the Company and/or one or more Subsidiaries or any combination thereof, as the
Administrator may deem appropriate, or any of the above performance criteria may be compared to the performance of a selected group
of comparison or peer companies, or a published or special index that the Administrator, in its sole discretion, deems appropriate,
or as compared to various stock market indices. The Administrator also has the authority to provide for accelerated vesting of any
Award based on the achievement of performance criteria specified in this paragraph. Any performance criteria that are financial
metrics, may be determined in accordance with United States Generally Accepted Accounting Principles (" <u>GAA</u> P") or
may be adjusted when established to include or exclude any items otherwise includable or excludable under GAAP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Default Vesting</u>. Unless otherwise set forth in an individual Award Agreement, each Award shall vest over a three (3) year period,
with one-third (1/3) of the Award vesting on the first annual anniversary of the date of grant and the remaining portion vesting annually
thereafter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Leaves of Absence</u>. Unless the Administrator provides otherwise, vesting of Awards granted hereunder will be suspended during
any Employee's unpaid leave of absence and will resume on the date the Employee returns to work on a regular schedule as determined
by the Administrator; <u>provided</u>, <u>however</u>, that no vesting credit will be awarded for the time vesting has been suspended
during such leave of absence. A Service Provider will not cease to be an Employee in the case of (i) any leave of absence approved by
the Company or the employing Subsidiary, although any leave of absence not provided for in the applicable employee manual of the Company
or employing Subsidiary needs to be approved by the Administrator, or (ii) transfers between locations of the Company or between the Company,
its Parent, or any Subsidiary. For purposes of Incentive Share Options, no leave of absence may exceed ninety (90) days, unless reemployment
upon expiration of such leave is guaranteed by statute or contract. If reemployment upon expiration of a leave of absence approved by
the Company or employing Subsidiary is not so guaranteed, then three (3) months following the 91st day of such leave any Incentive Share
Option held by the Participant will cease to be treated as an Incentive Share Option and will be treated for federal tax purposes as a
Nonqualified Share Option.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) In the event a Service Provider's regular level of time commitment in the performance of services for the Company, its Parent,
or any Subsidiary is reduced (for example, and without limitation, if the Service Provider is an Employee of the Company and the Employee
has a change in status from a full-time Employee to a part-time Employee) after the date of grant of any Award to the Service Provider,
the Administrator has the right in its sole discretion to (i) make a corresponding reduction in the number of Shares subject to any portion
of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (ii) in lieu of or in
combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In the event of any such reduction,
the Service Provider will have no right with respect to any portion of the Award that is so reduced or extended.

13. <u>Non-Transferability of Awards</u>. Unless determined otherwise by the Administrator, an Award may not be sold, pledged,
 assigned, hypothecated, transferred, or disposed of in any manner, except to the Participant's estate or legal representative,
 and may be exercised, during the lifetime of the Participant, only by the Participant, although the Administrator, in its
 discretion, may permit Award transfers for purposes of estate planning or charitable giving. If the Administrator makes an Award
 transferable, such Award will contain such additional terms
and conditions as the Administrator deems appropriate.

14. <u>Adjustments; Dissolution or Liquidation; Change in Control</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Adjustments</u>. In the event that any dividend or other distribution (whether in the form of cash, Shares, other securities, or
other property), recapitalization, share split, reverse share split, reorganization, merger, consolidation, split-up, spin-off, combination,
repurchase, or exchange of Shares or other securities of the Company, or other change in the corporate structure of the Company affecting
the Shares occurs such that an adjustment is determined by the Administrator (in its sole discretion) to be appropriate in order to prevent
dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan, then the Administrator shall,
in such manner as it may deem equitable, adjust the number and class of Shares which may be delivered under the Plan, the number, class
and price of Shares subject to outstanding awards, and the numerical limits in Section 4. Notwithstanding the preceding, the number of
Shares subject to any Award always shall be a whole number.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Dissolution or Liquidation</u>. In the event of the proposed dissolution or liquidation of the Company, the Administrator will
notify each Participant as soon as practicable prior to the effective date of such proposed transaction. The Administrator in its discretion
may provide for a Participant to have the right to exercise an Award, to the extent applicable, until ten (10) days prior to such transaction
as to all of the Shares covered thereby, including Shares as to which the Award would not otherwise be exercisable. In addition, the Administrator
may provide that any Company repurchase option or forfeiture rights applicable to any Award shall lapse 100%, and that any Award vesting
shall accelerate 100%, provided the proposed dissolution or liquidation takes place at the time and in the manner contemplated. To the
extent it has not been previously vested and, if applicable, exercised, an Award will terminate immediately prior to the consummation
of such proposed action.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Change in Control</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) In the event of a Change in Control, each outstanding Award shall be assumed or an equivalent award substituted by the acquiring or
successor corporation or a parent of the acquiring or successor corporation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Unless determined otherwise by the Administrator, in the
event that the successor corporation refuses to assume or substitute for the Award, the Participant shall fully vest in and have the
right to exercise the Award as to all of the Shares, including those as to which it would not otherwise be vested or exercisable, all
applicable restrictions will lapse, and all performance objectives and other vesting criteria will be deemed achieved at targeted levels.
If a Share Option is not assumed or substituted in the event of a Change in Control, the Administrator shall notify the Participant in
writing or electronically that the Share Option shall be exercisable, to the extent vested, for a period of up to fifteen (15) days from
the date of such notice, and the Share Option shall terminate upon the expiration of such period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) For the purposes of this Section 14(c), the Award shall be
considered assumed if, following the Change in Control, the Award confers the right to purchase or receive, for each Share subject to
the Award immediately prior to the Change in Control, the consideration (whether shares, cash, or other securities or property) received
in the Change in Control by holders of Shares for each Share held on the effective date of the transaction (and if holders were offered
a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding Shares); <u>provided</u>, <u>however</u>, that if such consideration received in the Change in Control is not solely common shares of the acquiring or successor
corporation or its parent, the Administrator may, with the consent of the acquiring or successor corporation, provide for the consideration
to be received, for each Share subject to the Award, to be solely common shares of the acquiring or successor corporation or its parent
equal in fair market value to the per share consideration received by holders of Shares in the Change in Control. Payments under this
provision may be delayed to the same extent that payment of consideration to the holders of the Shares in connection with the Change
in Control is delayed as a result of escrows, earn outs, holdbacks, or any other contingencies. Notwithstanding anything herein to the
contrary, an Award that vests, is earned, or is paid out upon the satisfaction of one or more performance goals will not be considered
assumed if the Company or the acquiring or successor corporation modifies any of such performance goals without the Participant's
consent; <u>provided</u>, <u>however</u>, that a modification to such performance goals only to reflect the acquiring or successor corporation's
post-Change in Control corporate structure will not be deemed to invalidate an otherwise valid Award assumption.

15. <u>Taxes</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>General</u>. It is a condition to each Award under the Plan that a Participant or such Participant's successor shall make
such arrangements that may be necessary, in the opinion of the Administrator or the Company, for the satisfaction of any federal, state,
local, or foreign withholding tax obligations that arise in connection with any Award granted under the Plan. The Company shall not be
required to issue any Shares or make any cash payment under the Plan unless such obligations are satisfied.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Share Withholding</u>. To the extent that Applicable Laws subject a Participant to tax withholding obligations, the Administrator
may permit such Participant to satisfy all or part of such obligations by having the Company, its Parent, or a Subsidiary withhold all or a portion of
any Share that otherwise would be issued to such Participant or by surrendering all or a portion of any Share that the Participant previously
acquired. Such Share shall be valued on the date withheld or surrendered. Any payment of taxes by assigning Shares to the Company, its
Parent, or a Subsidiary may be subject to restrictions, including any restrictions required by the Securities and Exchange Commission,
accounting, or other rules.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Discretionary Nature of Plan</u>. The benefits and rights provided under the Plan are wholly discretionary and, although provided
by the Company, do not constitute regular or periodic payments. Unless otherwise required by Applicable Laws, the benefits and rights
provided under the Plan are not to be considered part of a Participant's salary or
compensation or for purposes of calculating any severance, resignation, redundancy or other end of service payments, vacation,
bonuses, long-term service awards, indemnification, pension or retirement benefits, or any other payments, benefits, or rights of
any kind. By acceptance of an Award, a Participant waives any and all rights to compensation or damages as a result of the
termination of Service for any reason whatsoever insofar as those rights result or may result from this Plan or any Award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Code Section 409A</u>. Awards will be designed and operated in such a manner that they are either exempt from the application of,
or comply with, the requirements of Code Section 409A and will be construed and interpreted in accordance with such intent, except as
otherwise determined in the sole discretion of the Administrator. To the extent that an Award or payment, or the settlement or deferral
thereof, is subject to Code Section 409A, the Award will be granted, paid, settled, or deferred in a manner that will meet the requirements
of Code Section 409A, such that the grant, payment, settlement, or deferral will not be subject to the additional tax or interest applicable
under Code Section 409A.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Deferral of Award Settlement</u>. The Administrator, in its discretion, may permit selected Participants to elect to defer distributions
of Restricted Shares or RSUs in accordance with procedures established by the Administrator to assure that such deferrals comply with
applicable requirements of the Code. Any deferred distribution, whether elected by the Participant or specified by the Award Agreement
or the Administrator, shall comply with Code Section 409A, to the extent applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Limitation on Liability</u>. Neither the Company, nor its Parent, nor any Subsidiary, nor any person serving as Administrator shall
have any liability to a Participant in the event an Award held by the Participant fails to achieve its intended characterization under
applicable tax law.

16. <u>No Rights as a Service Provider</u>. Neither the Plan, nor an Award Agreement, nor any Award shall confer upon a Participant any
right with respect to continuing a relationship as a Service Provider, nor shall they interfere in any way with the right of the Participant
or the right of the Company, its Parent, or any Subsidiary to terminate such relationship at any time, with or without cause.

17. <u>Recoupment Policy</u>. All Awards granted under the Plan, all amounts paid under the Plan and all Shares issued under the Plan
shall be subject to recoupment, clawback, or recovery by the Company in accordance with Applicable Laws and with Company policy (whenever
adopted) regarding same, whether or not such policy is intended to satisfy the requirements of the U.S. Dodd-Frank Wall Street Reform
and Consumer Protection Act, the U.S. Sarbanes-Oxley Act, or other Applicable Laws, as well as any implementing regulations and/or listing
standards.

18. <u>Amendment and Termination of the Plan</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Amendment and Termination</u>. The Board may at any time amend, alter, suspend, or terminate the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Shareholder Approval</u>. The Company may obtain shareholder approval of any Plan amendment to the extent necessary or, as determined
by the Administrator in its sole discretion, desirable to comply with Applicable Laws, including any amendment that (i) increases the
number of Shares available for issuance under the Plan or (ii) changes the persons or class of persons eligible to receive Awards.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Effect of Amendment or Termination</u>. No amendment, alteration, suspension, or termination of the Plan will materially impair
the rights of any Participant with respect to outstanding Awards, unless mutually agreed otherwise between the Participant and the Administrator,
which agreement must be in writing and signed by the Participant and the Company. Termination of the Plan will not affect the Administrator's
ability to exercise the powers granted to it hereunder with respect to Awards granted under the Plan prior to the date of such termination.

19. <u>Conditions Upon Issuance of Shares</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Legal Compliance</u>. Shares will not be issued pursuant to an Award unless the exercise of such Award and the issuance and delivery
of such Shares will comply with Applicable Laws and will be further subject to the approval of counsel for the Company with respect to
such compliance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Investment Representations</u>. As a condition to the exercise or receipt of an Award, the Company may require the person exercising
or receiving such Award to represent and warrant at the time of any such exercise or receipt that the Shares are being purchased only
for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such
a representation is required or desirable.

20. <u>Severability</u>. Notwithstanding any contrary provision of the Plan or an Award Agreement, if any one or more of the provisions
(or any part thereof) of this Plan or an Award Agreement shall be held invalid, illegal, or unenforceable in any respect, such provision
shall be modified so as to make it valid, legal, and enforceable, and the validity, legality, and enforceability of the remaining provisions
(or any part thereof) of the Plan or Award Agreement, as applicable, shall not in any way be affected or impaired thereby.

21. <u>Inability to Obtain Authority</u>. The inability of the Company to obtain authority from any regulatory body having jurisdiction,
which authority is deemed by the Company's counsel to be necessary to the lawful issuance and sale of any Shares hereunder, will
relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority will
not have been obtained.

22. <u>Shareholder Approval</u>. The Plan will be subject to approval by the shareholders of the Company within twelve (12) months after
the date the Plan is adopted. Such shareholder approval will be obtained in the manner and to the degree required under Applicable Laws.
All Awards hereunder are contingent on approval of the Plan by shareholders. Notwithstanding any other provision of this Plan, if the
Plan is not approved by the shareholders within twelve (12) months after the date the Plan is adopted, the Plan and any Awards hereunder
shall be automatically terminated.

23. <u>Choice of Law</u>. The Plan will be governed by and construed in accordance with the internal laws
of Province of Ontario, Canada, without reference to any choice of law principles.

24. <u>Effective Date</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Plan shall be effective as of January 25, 2024 (as amended on June 28, 2024), the date on which the Plan was originally adopted
by the Board (the "Effective Date").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Unless terminated earlier under Section 18, this Plan shall terminate on January 25, 2034, ten years after the Effective Date.

## Exhibit 99.1

**Exhibit 99.1**

**Psyence BioMed Chief of Global Impact to speak at Psychedelic Science 2025**

*Investors, Entrepreneurs, and Industry Experts to Convene at the Premier Psychedelic Science Business Forum hosted by Multidisciplinary Association for Psychedelic Studies (MAPS)*

**DENVER – June 18, 2025** – Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company") today announced that Psychedelic Science 2025 ("PS2025") – the world's largest international gathering focused on psychedelic research, biopharma, medicine, policy, and culture, hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS) – has selected Mary-Elizabeth Gifford, Psyence BioMed's Chief of Global Impact, as a featured speaker in its Business Track at the highly anticipated conference taking place June 16–20, 2025, in Denver, Colorado. Gifford will join:

● Jody Aufrichtig – Founder and Board Chair, Psyence BioMed

● Tony Budden – Founder and CEO, PsyLabs

● Kabir Nath – CEO, COMPASS Pathways

● Doug Drysdale – CEO, Cybin Inc.

● Cosmo Feilding Mellen – CEO, Beckley Psytech

● Tim Schlidt – Co-Founder and Partner, Palo Santo

● Lindsay Hoover – Co-Founder and Managing Partner, JLS Fund

● Protik Basu – Managing Partner, Helena

"Collaboration and cooperation is the way forward to build this sector and to make the world better for all," said Psyence BioMed founder Aufrichtig who will be among other founders and experts in finance, entrepreneurship, and industry development anchoring this global event.

<br> "With billions of dollars flowing into psychedelic research, drug development, and emerging therapeutic models, PS2025's Business Track will offer essential insights into the commercial landscape of this field" according to the event organizers who also note: "From cross-sector policy innovators to regulatory changemakers and emerging leaders in psychedelic infrastructure, PS2025's Business Track spotlights the forces shaping how psychedelics move from research to real world impact."

PsyLabs CEO Budden accepted the invitation to PS2025 he said, because: "Truth, traceability, and transparency are essential in setting the gold standard for nature-derived pharmaceutical psychoactive compounds, and we welcome PS2025 as an important step forward in deepening the global conversation and elevating accountability – for the sake of our shareholders and also our patients."

Psyence BioMed has been invited to present on business ethics in a panel session, "We are the Guardrails: Profit with Purpose." As the Chief of Global Impact for Psyence Biomed, the first Nasdaq-listed biopharma with a focus on developing nature-derived (non-synthetic) psilocybin medicine for FDA approval, Gifford works in Washington, DC, to build bridges between research, regulation, and patient care.

A collaborative voice for psychedelic medicine, palliative care, and mental health on Capitol Hill and elsewhere, Gifford welcomed the invitation to elevate discussion of ethics at the upcoming MAPS gathering saying "Psychedelic business ethics sets a bright and golden standard for integrity that honors *both* patient care and shareholder value."

"A physician-led and patient-centered psychedelic biopharma, Psyence BioMed is guided by 'Profit with Purpose," said Gifford, adding, "I look forward to sharing our Psyence BioMed best practices at Psychedelic Science 2025."

**About Psyence Biomed:**

Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs, particularly in palliative care. The name 'Psyence' merges 'psychedelics' and 'science,' reflecting the company's commitment to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.

Learn more at www.psyencebiomed.com and on LinkedIn.

**About Psychedelic Science 2025**

Psychedelic Science 2025 (PS2025), hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS) is the world's leading psychedelic conference. Returning to the Colorado Convention Center in Denver from June 16-20, 2025, this five-day event brings together a global community of scientists, therapists, policymakers, cultural leaders, and advocates to explore the forefront of psychedelic research, therapy, and culture. PS2025 will feature expert speakers; hands-on workshops; community events with art, music, and mindfulness activities; and scholarship opportunities to support broad participation.

Since its inception in 2010, the Psychedelic Science conference series has fostered knowledge-sharing, collaboration, and community-building within the psychedelic ecosystem. Join thousands of attendees as we explore the transformative potential of psychedelics and shape the future of mental health, policy, and cultural understanding. For more information and registration details, visit psychedelicscience.org, and follow on X, Instagram, LinkedIn, and Facebook.

**ABOUT MAPS**

Founded in 1986, MAPS is a 501(c)(3) nonprofit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS' conference flagship, Psychedelic Science, has been the leading convening of the psychedelic community since 2010. MAPS incubated Lykos Therapeutics, a drug-development public benefit company, and the Zendo Project, a leader in psychedelic harm reduction. Since MAPS was founded, philanthropic donors and grantors have given more than $150 million to advance research, change drug policy, and evolve education in the field of psychedelics.

**Contact Information for Psyence Biomedical Ltd.**

Email: ir@psyencebiomed.com<br> Media Inquiries: media@psyencebiomed.com<br> General Information: info@psyencebiomed.com<br> Phone: +1 416-477-1708

**Investor Contact:**

Michael Kydd<br> Investor Relations Advisor<br> michael@psyencebiomed.com

**Forward Looking Statements**

This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "believe," "intend," "plan," "projection," "outlook" or words of similar meaning.

Forward-looking statements in this communication include statements regarding the progress of the Phase IIb clinical trial, and trial execution under the newly engaged CRO, the maintenance of Nasdaq listing requirements, and the creation of long-term shareholder value. These forward-looking statements are based on a number of assumptions, including the assumption that there will be no delays in the execution of the Phase IIb clinical trial implementation schedule, topline data from this trial will be positive, and that the demand for psychedelic-assisted therapy will continue to increase and that the Company will be able to maintain a share price trading above $1.00 per share. There can be no assurance that the Company will continue to maintain compliance with Nasdaq's continued listing requirements.

There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.

These risks and uncertainties include, among others: (i) delays in the execution of the Phase IIb trial; (ii) the ability of Psyence BioMed to maintain the listing of its common shares and warrants on Nasdaq; (iii) volatility in the price of the securities of Psyence BioMed due to a variety of factors, including the recent share consolidation, changes in the competitive and highly regulated industries in which Psyence BioMed operates, variations in performance across competitors, changes in laws and regulations affecting Psyence BioMed's business and changes in Psyence BioMed's capital structure. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of the Company's final prospectus (File No. 333-284444) filed with the Securities and Exchange Commission (the "SEC") on January 24, 2025 and other documents filed by Psyence BioMed from time to time with the SEC.

These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.

The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company's performance and operations.

## Exhibit 99.2

**Exhibit 99.2**

**Psyence BioMed Regains Full Compliance with Nasdaq Continued Listing Requirements**

**NEW YORK** – June 17, 2025 – Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), today announced that it has received formal notification from the Nasdaq Hearings Panel confirming that the Company has regained compliance with all applicable Nasdaq continued listing requirements. This confirmation follows a successful compliance hearing held on May 29, 2025.

"As a result of the decisive steps we've taken, Psyence BioMed is now fully compliant with Nasdaq's continued listing standards," said Dr. Neil Maresky, Chief Executive Officer of Psyence BioMed. "With a debt-free balance sheet, strong cash position, and a focused strategy, we believe we are well positioned to accelerate the commercialization of our nature-derived therapeutics and advance our mission to deliver evidence-based solutions – using psilocybin and Ibogaine – for unmet needs in palliative care, addiction, and related mental health conditions."

To support its efforts to regain compliance, the Company's shareholders approved a share consolidation (reverse stock split) at a Special Meeting of Stockholders held on April 16, 2025. The approved proposal authorized a reverse split at a ratio of up to 1-for-50, or a lesser amount at the discretion of the Board of Directors. The Board subsequently approved a final ratio of 1-for-7.97, which was implemented to increase the per-share trading price of the Company's common shares to meet Nasdaq's $1.00 minimum bid price requirement under Listing Rule 5550(a)(2).

"We appreciate the opportunity provided by the Nasdaq Hearings Panel to demonstrate our full compliance," added Dr. Maresky. "This reaffirms our commitment to strong corporate governance and long-term value creation for our shareholders."

**About Psyence BioMed**

Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs, particularly in palliative care. The name 'Psyence' merges 'psychedelics' and 'science,' reflecting the company's commitment to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.

Learn more at www.psyencebiomed.com and on LinkedIn.

**Contact Information for Psyence Biomedical Ltd.**

Email: ir@psyencebiomed.com

Media Inquiries: media@psyencebiomed.com

General Information: info@psyencebiomed.com

Phone: +1 416-477-1708

**Investor Contact:**

Michael Kydd

Investor Relations Advisor

michael@psyencebiomed.com

**Forward Looking Statements**

This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "believe," "intend," "plan," "projection," "outlook" or words of similar meaning.

Forward-looking statements in this communication include statements regarding the progress of the Phase IIb clinical trial, and trial execution under the newly engaged CRO, the maintenance of Nasdaq listing requirements, and the creation of long-term shareholder value. These forward-looking statements are based on a number of assumptions, including the assumption that there will be no delays in the execution of the Phase IIb clinical trial implementation schedule, topline data from this trial will be positive, and that the demand for psychedelic-assisted therapy will continue to increase and that the Company will be able to maintain a share price trading above $1.00 per share. There can be no assurance that the Company will continue to maintain compliance with Nasdaq's continued listing requirements.

There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.

These risks and uncertainties include, among others: (i) delays in the execution of the Phase IIb trial; (ii) the ability of Psyence BioMed to maintain the listing of its common shares and warrants on Nasdaq; (iii) volatility in the price of the securities of Psyence BioMed due to a variety of factors, including the recent share consolidation, changes in the competitive and highly regulated industries in which Psyence BioMed operates, variations in performance across competitors, changes in laws and regulations affecting Psyence BioMed's business and changes in Psyence BioMed's capital structure. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of the Company's final prospectus (File No. 333-284444) filed with the Securities and Exchange Commission (the "SEC") on January 24, 2025 and other documents filed by Psyence BioMed from time to time with the SEC.

These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.

The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company's performance and operations.